Interestingly, the Ezh2 inhibitor has been used as an anti-cancer drug (Tazemetostat) to promote the tumoricidal immune response and is currently approved for the treatment of follicular lymphoma and epithelioid sarcoma [39]. This evidence concerns the gene EZH2 and cancer.